Last updated on October 2017

MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas


Brief description of study

The blood brain barrier (BBB) is a major obstacle to drug delivery in the treatment of malignant brain tumors including Glioblastoma multiforme (GBM). MRI-guided laser ablation (MLA) has been noted to disrupt peritumoral BBB, which could then lead to increased access of new tumor antigens to the lymphovascular system and vice versa of immune effector cells to the tumor for effective activation of the immune system. Therefore the combination of MK-3475 and MLA as proposed in this protocol is hypothesized to create a therapeutic synergy in which MLA increases material access to promote immune activation and then MK-3475 maximizes these tumor-specific immune reactions to impart effective tumor control.

Clinical Study Identifier: NCT02311582

Contact Investigators or Research Sites near you

Start Over

David D Tran, M.D., Ph.D.

University of Florida
Gainesville, FL United States
  Connect »

Jian L Campian, M.D., Ph.D.

Washington University School of Medicine
Saint Louis, MO United States
  Connect »